Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North Central Cancer Treatment Group study N0272 (Alliance/NCCTG)
- Citation:
- J Neurooncol vol 143 (3) 573-81
- Year:
- 2019
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 8
- Parents:
- 641
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10CA180790, U10CA180844, UG1CA189863, U24CA196171
- Corr. Author:
- Authors:
- Kurt A. Jaeckle S K. Anderson Erin L. Twohy Jesse G. Dixon Caterina Giannini Robert Jenkins Merrill J. Egorin Jann N. Sarkaria Paul D. Brown P J. Flynn John Schwerkoske Jan C. Buckner Eva Galanis
- Networks:
- LAPS-MN026, METROMIN, MN017
- Study
- NCCTG-N0272
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords: